Eubiologics IPO Part 2 - Growth Potential & Appropriate Valuation Level
*Â In Part 2 (as below), I examined the company's business fundamentals in more detail along with its growth potential and appropriate valuation...
355 Views
Eubiologics IPO Part 1 - Schedule, Financials & Valuation
Eubiologics is a very "young" vaccine company that develops an oral cholera vaccine product called "Euvichol". This company will be Korea's first...
537 Views
Celltrion Healthcare IPO - Early Review on Key Issues
Celltrion Healthcare, which is Celltrion (068270)’s overseas sales and marketing unit, submitted the application for preliminary screening for...
422 Views
SillaJen IPO Part 5 -Â Revenue & Valuation Estimates with Pexa-Vec's First Commercialization Year
We need to examine the size of SillaJen's expected sales in 2020, which is the reference year for its entire valuation. With an assumption that...
498 Views
SillaJen IPO Part 4 - IPO Price & Post-IPO Risks
SillaJen IPO price was set at ₩15,000, the lowest end of the indicative price band, after conducting the demand survey from (Nov 23-24) the...
460 Views